Abstract：
:Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their obligation for wise consumption of restricted healthcare resources and protection of the safety of their coworkers. Nonurgent in-person clinic visits should be postponed or conducted remotely via phone or teleconference. Prostate cancer screening, imaging, and biopsies may be suspended in general. Treatment may be safely deferred in low and intermediate risk patients. Surgery may be delayed in most high-risk patients and neoadjuvant ADT is generally not advocated prior to surgery. Initiation of long-term ADT coupled with EBRT subsequent to the pandemic may be favored as a feasible alternative in high-risk and very high-risk disease. In patients with cN1 disease, treatment within 6 weeks is advocated. Presurgery assessment should include testing for COVID-19 and preferably a chest imaging. In the presence of SARS-CoV-2 infection, surgery should be postponed whenever possible. All protective measurements suggested by national/international authorities must to be diligently followed during perioperative period. Strict precautions specific to laparoscopic/robotic surgery are required, considering the unproven but potential risk of aerosolization of SARS-CoV-2 virus and spillage with pneumoperitoneum. Regarding radiotherapy, shortest safe EBRT regimen should be favored and prophylactic whole pelvic RT and brachytherapy avoided. Chemotherapy should be avoided whenever possible.
journal_name
Prostate Cancer Prostatic Disjournal_title
Prostate cancer and prostatic diseasesauthors
Obek C,Doganca T,Argun OB,Kural ARdoi
10.1038/s41391-020-0258-7subject
Has Abstractpub_date
2020-09-01 00:00:00pages
398-406issue
3eissn
1365-7852issn
1476-5608pii
10.1038/s41391-020-0258-7journal_volume
23pub_type
杂志文章,评审abstract：:Prostate cancer is the commonest non-skin malignancy in the United States and has a substantial mortality rate despite the use of PSA-based screening. Furthermore, therapy for prostate cancer by surgery, radiotherapy or hormonal manipulation carries a significant risk of treatment-related morbidity. Recent analysis of...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500412
更新日期：2000-11-01 00:00:00
abstract：:Benign prostatic hyperplasia (BPH) is a highly prevalent, age-related disease. As the world population continues to grow and life expectancy increases, the population of men suffering from BPH will expand. A greater emphasis will be placed on quality of life. The BPH patient of the future will also have greater expect...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500370
更新日期：1999-12-01 00:00:00
abstract：:'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500963
更新日期：2007-01-01 00:00:00
abstract：:The aim of this paper is to review the inhibitors of apoptosis proteins, a recently discovered group of caspase inhibitors. We will briefly review the relevance of apoptosis in prostate cancer and some of the control mechanisms, before describing the structure, function and regulation of these molecules. Lastly, we wi...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500502
更新日期：2001-01-01 00:00:00
abstract：BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2014.28
更新日期：2014-12-01 00:00:00
abstract：BACKGROUND:Androgen deprivation therapy (ADT) has been shown to improve survival for men with intermediate and high-risk prostate cancer undergoing external-beam radiation therapy (EBRT). Using data from a community-based prospective disease registry, we investigated usage of EBRT with or without neoadjuvant ADT. METH...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-018-0084-3
更新日期：2019-03-01 00:00:00
abstract：:The aim of the study was to evaluate factors of progression after radical prostatectomy in patients with bladder neck invasion (BNI). From 1988 to 2006, 1395 patients underwent radical prostatectomy, 120 (8.6%) had microscopic BNI (pT4 N0, TNM 2002). Group 1 was defined as BNI alone, group 2 as BNI plus extracapsular ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4501009
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-019-0136-3
更新日期：2019-12-01 00:00:00
abstract：BACKGROUND:The worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development. METHODS:This study consisted of 11 541 men with co...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2012.54
更新日期：2013-06-01 00:00:00
abstract：:The relationships between serum level of testosterone (T) and prostate cancer (PCa) are complex. The present study evaluated whether presence of PCa alters serum T levels. Subjects were 125 patients with clinically localized PCa treated using radical prostatectomy (RP), for whom pretreatment T levels were recorded. We...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2008.35
更新日期：2009-01-01 00:00:00
abstract：:The Gyrus system uses bipolar electrocautery with saline irrigation to vaporize prostatic tissue and is compared to transurethral resection of the prostate (TURP) in a randomized prospective study with 1 y follow-up. Outcomes measured were fluid absorption, blood loss, period of catheterization, hospital stay, symptom...
journal_title：Prostate cancer and prostatic diseases
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1038/sj.pcan.4500631
更新日期：2003-01-01 00:00:00
abstract：:Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2011.28
更新日期：2011-12-01 00:00:00
abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,多中心研究
doi：10.1038/pcan.2014.41
更新日期：2015-03-01 00:00:00
abstract：:The aim of the present study was to investigate the differential expression of erythropoietin receptor (EPOR) in prostate carcinoma (PCa), high-grade prostatic intraepithelial neoplasia (PIN), prostatic hyperplasia (BPH) lesions and normal prostatic tissues by immunohistochemistry; and to test the hypothesis that upre...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500995
更新日期：2008-01-01 00:00:00
abstract：BACKGROUND:Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METH...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2017.19
更新日期：2017-09-01 00:00:00
abstract：:As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500210
更新日期：1997-12-01 00:00:00
abstract：BACKGROUND:To assess the added value of biopsy factors, like maximum cancer length in a core (MCL), cumulative cancer length (CCL), cumulative length of positive cores (CLPC), percentage of cancer involvement in positive cores (CIPC) and the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria i...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2015.26
更新日期：2015-12-01 00:00:00
abstract：INTRODUCTION:Recent technological advancements and the introduction of modern anatomical and functional sequences have led to a growing role for multiparametric magnetic resonance imaging (mpMRI) in the detection, risk assessment and monitoring of early prostate cancer. This includes men who have been diagnosed with lo...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/s41391-018-0077-2
更新日期：2019-03-01 00:00:00
abstract：INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500752
更新日期：2004-01-01 00:00:00
abstract：OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,meta分析,评审
doi：10.1038/pcan.2014.17
更新日期：2014-09-01 00:00:00
abstract：BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.67
更新日期：2017-06-01 00:00:00
abstract：BACKGROUND:Approximately 29-38% of all positive surgical margins (PSMs) at radical prostatectomy (RP) involve the apex. The prognostic significance of apical PSM remains unclear. We therefore compared the long-term oncologic outcomes of men with apical PSMs to those with negative PSMs, apical and other PSMs, and other ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.45
更新日期：2016-12-01 00:00:00
abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2013.33
更新日期：2013-12-01 00:00:00
abstract：BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2012.41
更新日期：2013-03-01 00:00:00
abstract：BACKGROUND:Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatmen...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-020-00288-y
更新日期：2020-09-28 00:00:00
abstract：:To describe practice patterns of primary care physicians (PCPs) for the diagnosis, treatment and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), we surveyed 556 PCPs in Boston, Chicago, and Los Angeles (RR=52%). Only 62% reported ever seeing a patient like the one described in the vignette. I...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2009.9
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS:We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametri...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2014.33
更新日期：2014-12-01 00:00:00
abstract：BACKGROUND:Berbamine (BBM) has been reported with antitumor activities. BBM inhibited the growth of prostate cancer (PCa) cells and caused vacuolization of mitochondria in preliminary study. We hypothesized BBM could enhance apoptosis of PCa cells through mitochondrial pathway. METHODS:Growth of PC-3 and LNCaP cells t...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.29
更新日期：2016-12-01 00:00:00
abstract：:Dose-escalated conformal radiotherapy is increasingly being used to radically treat prostate cancer with encouraging results and minimal long-term toxicity, yet little is known regarding the response of normal or malignant prostate cells to ionizing radiation (IR). To clarify the basis for cell killing during prostate...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500628
更新日期：2003-01-01 00:00:00
abstract：:Side effects accompanying androgen deprivation therapy (ADT), including sarcopenia, loss of bone mass and reduction in muscle strength, can compromise physical function, particularly in older patients. Exercise, specifically resistance training, may be an effective and cost-efficient strategy to limit or even reverse ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/sj.pcan.4500975
更新日期：2007-01-01 00:00:00
